Stericycle Inc
Change company Symbol lookup
Select an option...
SRCL Stericycle Inc
TWTR Twitter Inc
CSTL Castle Biosciences Inc
LH Laboratory Corporation of America Holdings
ET Energy Transfer LP
BG Bunge Ltd
MSB Mesabi Trust
TRC Tejon Ranch Co
RMO Romeo Power Inc
RHI Robert Half International Inc

Industrials : Commercial Services & Supplies | Small Cap Blend
Company profile

Stericycle, Inc. is a business-to-business services company. The Company serves customers in the United States and approximately 16 other countries worldwide with solutions for regulated waste and compliance services and secure information destruction services. The Company operates through two segments: Regulated Waste and Compliance Services, and Secure Information Destruction Services. Regulated Waste and Compliance Services segment provides its services to the customers in the United States, Brazil, Canada, Ireland, the Netherlands, Portugal, the Republic of Korea, Romania, Spain and the United Kingdom. Secure Information Destruction Services segment under the Shred-it brand provides its services in the United States, Australia, Belgium, Canada, France, Germany, Ireland, Luxembourg, the Netherlands, Portugal, Spain, Singapore and the United Kingdom. Secure Information Destruction Services are also provided in the United Arab Emirates through a joint venture.

Closing Price
Day's Change
0.74 (1.72%)
B/A Size
Day's High
Day's Low
(Below Average)

10-day average volume:

Evofem Biosciences Discusses Innovative Woman-Controlled Contraceptive with The Stock Day Podcast

9:01 am ET August 1, 2022 (Newsfile) Print

Phoenix, Arizona--(Newsfile Corp. - August 1, 2022) - The Stock Day Podcast welcomed Evofem Biosciences (NASDAQ: EVFM) ("the Company"), an innovator in women's sexual and reproductive health and the maker of hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate). Evofem's CEO, Saundra Pelletier, joined Stock Day host Sever Copley.

"What is Phexxi and how does it fit into the contraceptive landscape?" asked Copley. "Phexxi is the first and only birth control product that has no hormones, no systemic activity in the body, is the only birth control product that does not negatively impact a woman's ovaries and is used only when you need it and never when you don't," explained Pelletier. "There are 23 million women in the United States that will not use hormones," she said. "Phexxi matters because it is time that women are empowered to have sex on demand and be protected on their terms, just like men have had."

"Does it also prevent sexually transmitted diseases?" asked Copley. "We just completed the EVOGUARD trial and are going to report top-line data from this landmark Phase III study in October," said Pelletier. Expanding the FDA-approved label should "double the market opportunity," she shared. "This asset could easily represent a billion-dollar opportunity."

"What impact are you seeing from the Roe vs. Wade ruling on Phexxi utilization?" asked Copley. "We are seeing utilization grow, and we are seeing it grow immediately and in several different areas," said Pelletier. "Women are starting to gravitate towards Phexxi and doctors are starting to prescribe Phexxi to a broader base of women," she continued, adding that investors are also starting to take notice. "When women can't get access to abortion, they have to protect themselves now more than ever."

The conversation then turned to the Company's clinical trial progress. "We will release top-line data in the fourth quarter of this year from our registrational trial evaluating Phexxi for the prevention of chlamydia and gonorrhea, and then we will submit to the FDA," said Pelletier. "We have fast track designation from the FDA, which should give us an expedited review and potential approval to expand our label for Phexxi by the end of 2023."

To close the interview, Pelletier elaborated on the significance of the Evofem's revolutionary product, especially in regard to the changing landscape of women's health. She also encouraged listeners to keep up-to-date on the Company's latest projects as they continue to address unmet needs in women's sexual and reproductive health.

Since the interview, the Departments of Labor, Health and Human Services, and Treasury released guidance clarifying that group health plans and insurers must cover contraceptives at no cost to individuals and that enforcement action will be taken to ensure that participants receive this coverage with no cost sharing. This new guidance is expected to catalyze further Phexxi growth within the multi-billion-dollar U.S. contraceptive market.

To hear the entire interview with Saundra Pelletier, follow the link to the podcast here:

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.


Stock Day Media

(602) 821-1102

To view the source version of this press release, please visit

comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.